ECSP23018458A - Proteínas de unión restringidas activadas de forma condicional - Google Patents

Proteínas de unión restringidas activadas de forma condicional

Info

Publication number
ECSP23018458A
ECSP23018458A ECSENADI202318458A ECDI202318458A ECSP23018458A EC SP23018458 A ECSP23018458 A EC SP23018458A EC SENADI202318458 A ECSENADI202318458 A EC SENADI202318458A EC DI202318458 A ECDI202318458 A EC DI202318458A EC SP23018458 A ECSP23018458 A EC SP23018458A
Authority
EC
Ecuador
Prior art keywords
tumor
binding proteins
conditionally activated
constructs
restricted binding
Prior art date
Application number
ECSENADI202318458A
Other languages
English (en)
Spanish (es)
Inventor
Tseng-Hui Chen
Jeremiah Degenhardt
Chad May
Patricia Culp
Danielle Dettling
Robert B Dubridge
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP23018458A publication Critical patent/ECSP23018458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ECSENADI202318458A 2020-08-17 2023-03-16 Proteínas de unión restringidas activadas de forma condicional ECSP23018458A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17

Publications (1)

Publication Number Publication Date
ECSP23018458A true ECSP23018458A (es) 2023-04-28

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202318458A ECSP23018458A (es) 2020-08-17 2023-03-16 Proteínas de unión restringidas activadas de forma condicional

Country Status (16)

Country Link
US (1) US20240026011A1 (https=)
EP (1) EP4196503A2 (https=)
JP (1) JP7832926B2 (https=)
KR (1) KR20230048146A (https=)
CN (1) CN116419925A (https=)
AR (1) AR123266A1 (https=)
AU (1) AU2021329290A1 (https=)
CA (1) CA3191431A1 (https=)
CL (1) CL2023000477A1 (https=)
CO (1) CO2023002164A2 (https=)
EC (1) ECSP23018458A (https=)
IL (1) IL300598A (https=)
MX (1) MX2023002002A (https=)
PE (1) PE20230856A1 (https=)
TW (1) TW202214707A (https=)
WO (1) WO2022040128A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2023164551A1 (en) * 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
EP4583921A1 (en) * 2022-09-07 2025-07-16 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
WO2024147897A2 (en) * 2023-01-05 2024-07-11 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014010482A (en) 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
KR20230041739A (ko) 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
IL302613B2 (en) * 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2020181140A1 (en) * 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
US20240026011A1 (en) 2024-01-25
AR123266A1 (es) 2022-11-16
EP4196503A2 (en) 2023-06-21
JP2023538366A (ja) 2023-09-07
CL2023000477A1 (es) 2023-11-10
WO2022040128A3 (en) 2022-04-07
AU2021329290A1 (en) 2023-04-13
CA3191431A1 (en) 2022-02-24
IL300598A (en) 2023-04-01
WO2022040128A2 (en) 2022-02-24
PE20230856A1 (es) 2023-05-29
TW202214707A (zh) 2022-04-16
JP7832926B2 (ja) 2026-03-18
KR20230048146A (ko) 2023-04-10
CN116419925A (zh) 2023-07-11
MX2023002002A (es) 2023-07-06
CO2023002164A2 (es) 2023-03-07

Similar Documents

Publication Publication Date Title
ECSP23018458A (es) Proteínas de unión restringidas activadas de forma condicional
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
CY1122005T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
PE20170585A1 (es) Moleculas de union a antigeno biespecificas activadoras de celulas t
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
UY39324A (es) Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
CL2024003472A1 (es) Complejos radiofarmacéuticos dirigidos al antígeno prostático específico de membrana y sus combinaciones.
MX2021010451A (es) Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo.
CO2025002261A2 (es) Degradación de proteínas dirigida de parp14 para usar en terapia
CO2023014772A2 (es) Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas
AR113010A1 (es) Proteínas de unión condicionalmente activadas limitadas
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.